Biocept Stock

Biocept Debt / Assets

Delisted

The Debt-to-Assets Ratio of Biocept (BIOC) as of Aug 4, 2026 is 0.08. In the previous year, Debt-to-Assets Ratio was 0.04 — a change of 88.29% (higher).

Debt / Assets

0.08

YoY

88.29%

Last updated:

Debt-to-Assets Ratio of Biocept is 2026 0.08 . Debt-to-Assets Ratio of Biocept was 2025 0.04 . It decreases by 88.29% higher compared to the previous year.
Access this data via the Eulerpool API

Biocept Stock analysis

What does Biocept do? Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biocept stock

Debt-to-Assets Ratio of Biocept is 0.08 in 2026.

Debt-to-Assets Ratio of Biocept changed from 0.04 to 0.08, representing a 88.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt-to-Assets Ratio Biocept since 2006 – with annual values, charts, and detailed analysis.

The Debt-to-Assets ratio measures what percentage of a company's assets are financed through debt. Higher ratios indicate greater financial risk.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt-to-Assets Ratio's Biocept with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Biocept

All Key Metrics — Biocept